BGOG-ov-18

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.

 

Study sites

  • AZ Maria Middelares, Gent
  • CHU Sart Tilman, Liège
  • Cliniques Universitaires St. Luc, Bruxelles
  • Jessaziekenhuis, Hasselt
  • UZ Antwerpen, Edegem
  • UZ Gent, Gent
  • UZ Leuven, Leuven

 

Professional Area

Unlock